Ownership and insider activity for Cardiff Oncology, Inc. (CRDF): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Price
| Price | $1.35 |
| Market Cap | $104M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-14 | PACE GARY W | P-Purchase | 687,285 | $1000K |
| 2026-07-14 | PACE GARY W | P-Purchase | 687,285 | $914K |
| 2026-07-14 | Mohindru Mani | P-Purchase | 34,364 | $50K |
| 2026-07-14 | Mohindru Mani | P-Purchase | 34,364 | $46K |
| 2026-06-18 | Mohindru Mani | P-Purchase | 24,703 | $30K |
| 2026-06-18 | PACE GARY W | P-Purchase | 30,000 | $37K |
| 2026-06-11 | Armitage James O | A-Award | 40,565 | $64K |
| 2026-06-11 | White Lale | A-Award | 40,565 | $64K |
| 2026-06-11 | TANNENBAUM RENEE P | A-Award | 40,565 | $64K |
| 2026-06-11 | Markin Rodney S | A-Award | 40,565 | $64K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.9M | $8.2M | $11.5M | $10.2M | $131.0M | $11.9M | $16.3M | $21.7M | $51.5M | $17.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $128.9M | $88.9M | $53.2M | $40.3M | $40.8M |
| Receivables | $100460 | $77095 | $167755 | $203480 | $320000 | $535000 | $771000 | $288000 | $773000 | $182000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $39.0M | $9.5M | $12.8M | $11.4M | $133.4M | $146.1M | $111.3M | $77.4M | $95.1M | $60.1M |
| Property, Plant & Equipment | $3.8M | $2.4M | $1.3M | $1.6M | $967000 | $3.2M | $3.5M | $2.9M | $2.1M | $1.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $44.0M | $12.3M | $14.2M | $13.1M | $134.7M | $149.5M | $116.2M | $81.6M | $97.2M | $61.9M |
| Accounts Payable | $1.1M | $825244 | $664840 | $656304 | $1.4M | $1.4M | $2.0M | $2.0M | $4.8M | $8.1M |
| Short-term Debt | $2.4M | $1.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $7.8M | $3.9M | $3.0M | $4.8M | $6.1M | $6.6M | $7.8M | $10.4M | $13.4M | $16.4M |
| Long-term Debt | $14.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $24.2M | $5.8M | $4.1M | $5.8M | $6.6M | $9.1M | $9.8M | $11.9M | $14.2M | $16.5M |
| Retained Earnings | -$148.1M | -$173.0M | -$192.2M | -$208.9M | -$231.5M | -$259.8M | -$298.1M | -$339.5M | -$384.2M | -$430.0M |
| Total Equity | $19.8M | $6.5M | $10.1M | $7.3M | $128.2M | $140.4M | $106.3M | $69.7M | $82.9M | $45.4M |
| Total Debt | $16.5M | $1.3M | 0 | $1.7M | $869000 | $3.1M | $2.7M | $2.1M | $1.5M | $832000 |
| Net Debt | -$21.4M | -$6.9M | -$11.5M | -$8.5M | -$130.1M | -$137.7M | -$102.6M | -$72.7M | -$90.2M | -$57.5M |
| Working Capital | $31.2M | $5.5M | $9.8M | $6.6M | $127.2M | $139.6M | $103.5M | $67.0M | $81.6M | $43.7M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 3.30 |
Profitability
| Return on Equity | -103.08% |
| Return on Invested Capital | -156.60% |
| Return on Assets | -107.29% |
| Gross Margin | 100.00% |
| Operating Margin | -8320.08% |
| Net Margin | -7884.06% |
Related companies: APLT · CRBP · ELTX · FBRX · IPHA · MIST · MOLN
Explore sector: Healthcare · Biotechnology
More sections of CRDF: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks